Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
07/14 ASTELLAS PHARMA : "Pharmaceutical Composition for Modified Use" in Patent Applic..
07/09DJCorrections & Amplifications -- WSJ
07/07 ASTELLAS PHARMA : Recent Findings from Astellas Pharma, Inc. Has Provided New Da..
07/06 ASTELLAS PHARMA : Named to FTSE4Good Sustainability Index for the Fifth Consecut..
06/28 ASTELLAS PHARMA : Farma Brasil Among Top 3 Workplaces in Brazilian Pharmaceutica..
06/23 ASTELLAS PHARMA : Findings from Astellas Pharma, Inc. Provides New Data about Th..
06/23 ASTELLAS PHARMA : The Institute of Medical Science, the University of Tokyo and ..
06/20 ASTELLAS PHARMA : NIH won't cut price of taxpayer-funded prostate cancer drug
06/16 ASTELLAS PHARMA : Excelra Enters into a Drug Repurposing Collaboration with Aste..
06/09 ASTELLAS PHARMA : and Medivation Initiate Phase III Trial of Enzalutamide in Pat..
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 For The Real Relypsa Puzzle Look Beyond The Takeover
07/15 Therapy Focus - Another Try For FGFR Inhibitors
07/11 TIGENIX : Buy A Mostly De-Risked Asset And Get The Pipeline For Free
07/06 2016 Share Gainers Signal Flight To Safety
07/06 Tigenix The Latest To Find Stem Cell Appetite In Japan
Advertisement
Financials ( JPY)
Sales 2017 1 339 754 M
EBIT 2017 280 000 M
Net income 2017 197 265 M
Finance 2017 478 230 M
Yield 2017 2,08%
P/E ratio 2017 17,69
P/E ratio 2018 16,38
EV / Sales 2017 2,31x
EV / Sales 2018 2,14x
Capitalization 3 566 731 M
More Financials
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 1 865  JPY
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yukihiko Sato President & Chief Executive Officer
Masafumi Nogimori Chairman
Yasumasa Masuda Senior Executive Officer & Head-Finance
Mitsunori Matsuda Senior Executive Officer & GM-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-3.61%33 577
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
More Results